Aspartate Aminotransferase to Platelet Ratio Index (APRI)
APRI is a simple noninvasive index estimating liver fibrosis from the ratio of AST to platelet count.
Indications for Use
Used to non‑invasively stratify liver fibrosis when biopsy or elastography is unavailable, especially in chronic hepatitis C and chronic hepatitis B, to rule out or suggest significant fibrosis or cirrhosis. Provides moderate diagnostic accuracy (AUC ~0.72–0.83 across fibrosis stages) based on large meta‑analyses 1 [Level II evidence]; 2 [Level I evidence]. Helps triage for antiviral treatment and identify low‑risk patients suitable for routine follow‑up.
Insights & Cautions
Offers low‑cost exclusion of advanced fibrosis but has limited accuracy: good NPV at low cutoffs (≈0.5) but poor PPV at higher thresholds (≥1.5) and often underperforms FIB‑4 for ≥F3 disease (systematic review of 286 studies 1 [Level I evidence]). Can be falsely elevated with hepatic inflammation or acute injury. Best used only as an initial triage tool, ideally combined with elastography for confirmation.